Long-acting Muscarinic Antagonist Versus Inhaled Corticosteroid when Added to Long-acting β-agonist for COPD: A Meta-analysis

References

• Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet 2012; 379(9823):1341–1351. Epub 2012/02/09.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187(4):347–65. Epub 2012/08/11.
   PubMed Web of Science ®Google Scholar
• Price D, West D, Brusselle G, Gruffydd-Jones K, Jones R, Miravitlles M, et al. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. Int J Chron Obstruct Pulmon Dis 2014; 9:889–904. Epub 2014/09/12.
   PubMed Web of Science ®Google Scholar
• Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 9:CD006829. Epub 2012/09/14.
   Google Scholar
• Ernst P, Suissa S. Systemic effects of inhaled corticosteroids. Curr Opin Pulm Med 2012; 18(1):85–89. Epub 2011/11/25.
   PubMed Web of Science ®Google Scholar
• Oba Y, Sarva ST, Dias S. Efficacy and safety of long-acting beta-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis. Thorax 2015; 71(1): 15–25. Epub 2015/10/23.
   PubMed Web of Science ®Google Scholar
• Magnussen H, Disse B, Rodriguez-Roisin R, Kirsten A, Watz H, Tetzlaff K, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 2014; 371(14):1285–1294. Epub 2014/09/10.
   PubMed Web of Science ®Google Scholar
• Halpin DM, Decramer M, Celli B, Kesten S, Leimer I, Tashkin DP. Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4-source UPLIFT(R) trial. Lung 2011; 189(4):261–268. Epub 2011/06/17.
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol 2011; 64(4):380–382. Epub 2010/12/28.
   PubMed Web of Science ®Google Scholar
• Dechartres A, Trinquart L, Boutron I, Ravaud P. Influence of trial sample size on treatment effect estimates: meta-epidemiological study. BMJ 2013; 346:f2304. Epub 2013/04/26.
   Google Scholar
• Nuesch E, Trelle S, Reichenbach S, Rutjes AW, Tschannen B, Altman DG, et al. Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study. BMJ 2010; 341:c3515. Epub 2010/07/20.
   Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327(7414):557–560. Epub 2003/09/06.
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence—imprecision. J Clin Epidemiol 2011; 64(12):1283–1293. Epub 2011/08/16.
   PubMed Web of Science ®Google Scholar
• Vogelmeier C, Paggiaro PL, Dorca J, Sliwinski P, Mallet M, Kirsten A, et al. Efficacy of aclidinium/formoterol fixed-dose combination versus salmeterol/fluticasone in COPD. Eur Respir J 2015; 46(suppl 59):PA2960.
   Google Scholar
• Zhong N, Wang C, Zhou X, Zhang N, Humphries M, Wang L, et al. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. Int J Chron Obstruct Pulmon Dis 2015; 10:1015–1026. Epub 2015/06/18.
   PubMed Web of Science ®Google Scholar
• Vogelmeier CF, Bateman ED, Pallante J, Alagappan VK, D'Andrea P, Chen H, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med 2013; 1(1):51–60. Epub 2013/12/11.
   PubMed Web of Science ®Google Scholar
• Donohue JF, Worsley S, Zhu CQ, Hardaker L, Church A. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respir Med 2015; 109(7):870–881. Epub 2015/05/27.
   PubMed Web of Science ®Google Scholar
• Singh D, Worsley S, Zhu CQ, Hardaker L, Church A. Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial. BMC Pulm Med 2015; 15:91. Epub 2015/08/20.
   PubMed Web of Science ®Google Scholar
• Jones PW, Beeh KM, Chapman KR, Decramer M, Mahler DA, Wedzicha JA. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med 2014; 189(3):250–255. Epub 2014/01/05.
   PubMed Web of Science ®Google Scholar
• Kon SS, Canavan JL, Jones SE, Nolan CM, Clark AL, Dickson MJ, et al. Minimum clinically important difference for the COPD Assessment Test: a prospective analysis. Lancet Respir Med 2014; 2(3):195–203. Epub 2014/03/14.
   PubMed Web of Science ®Google Scholar
• Janson C, Larsson K, Lisspers KH, Stallberg B, Stratelis G, Goike H, et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting beta2 agonist: observational matched cohort study (PATHOS). BMJ 2013; 346:f3306. Epub 2013/05/31.
   Google Scholar
• Sun X, Briel M, Walter SD, Guyatt GH. Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ 2010; 340:c117. Epub 2010/04/01.
   Google Scholar
• Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008; 300(20):2407–2416. Epub 2008/11/27.
   PubMed Web of Science ®Google Scholar
• Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med 2009; 169(3):219–229. Epub 2009/02/11.
   PubMedGoogle Scholar
• Sin DD, Tashkin D, Zhang X, Radner F, Sjobring U, Thoren A, et al. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet 2009; 374(9691):712–719. Epub 2009/09/01.
   PubMed Web of Science ®Google Scholar
• Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014; 3:CD010115. Epub 2014/03/13.
   Google Scholar
• Ernst P, Saad N, Suissa S. Inhaled corticosteroids in COPD: the clinical evidence. Eur Respir J 2015; 45(2):525–537. Epub 2014/12/30.
   PubMed Web of Science ®Google Scholar
• Novartis Pharmaceuticals. QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study. ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT01782326 (accessed 21 December 2015).
   Google Scholar
• GlaxoSmithKline. A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD). ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT02164513 (accessed 21 December 2015).
   Google Scholar